Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways

Oncogene

Volumn 29, Issue 37, 2010, Pages 5182-5192

  Lee, S H ^a   Bahn, J H ^a   Whitlock, N C ^a   Baek, S J ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

apoptosis; ATF2; ATF3; colorectal cancer; Tolfenamic acid

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLFENAMIC ACID; ANTHRANILIC ACID DERIVATIVE; ATF2 PROTEIN, HUMAN; ATF3 PROTEIN, HUMAN; DNA;

APOPTOSIS; ARTICLE; BINDING SITE; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; GENE DELETION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; ANTHRANILIC ACIDS; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; ORTHO-AMINOBENZOATES;

ANIMALIA;

EID: 77956898560     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.251     Document Type: Article

References (45)

1. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. (2006). Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98: 855-868.
2. Abdelrahim MB, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD et al. (2007). Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 67: 3286-3294.
3. Allan AL, Albanese C, Pestell RG, LaMarre J. (2001). Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J Biol Chem 276: 27272-27280.
4. Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH. (2004). Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 25: 2425-2432.
5. Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S et al. (2008). Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci USA 105: 1674-1679.
6. Bhoumik A, Ronai Z. (2008). ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 7: 2341-2345.
7. Bottone Jr FG., Martinez JM, Alston-Mills B, Eling TE. (2004). Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 25: 349-357.
8. Bottone Jr FG, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE. (2005). The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 4: 693-703.
9. Brown SL, Sekhar KR, Rachakonda G, Sasi S, Freeman ML. (2008). Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2)-regulated stress pathway. Cancer Res 68: 364-368.
10. Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, Oshiro S et al. (2000). Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element. Blood 96: 2140-2148.
11. Chen HH, Wang DL. (2004). Nitric oxide inhibits matrix metallopro-teinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 65: 1130-1140.
12. Cho KN, Sukhthankar M, Lee SH, Yoon JH, Baek SJ. (2007). Green tea catechin (-)-epicatechin gallate induces tumour suppressor protein ATF3 via EGR-1 activation. Eur J Cancer 43: 2404-2412.
13. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ et al. (2008). Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68: 9663-9670.
14. Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H et al. (2002). ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 21: 7488-7496.
15. Fuchs SY, Tappin I, Ronai Z. (2000). Stability of the ATF2 transcription factor is regulated by phosphorylation and dephos-phorylation. J Biol Chem 275: 12560-12564.
16. Gupta RA, Dubois RN. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21.
17. Hai T, Hartman MG. (2001). The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273: 1-11.
18. Hai TW, Liu F, Allegretto EA, Karin M, Green MR. (1988). A family of immunologically related transcription factors that includes multiple forms of ATF and AP-1. Genes Dev 2: 1216-1226.
19. Hansen PE. (1994). Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 75(Suppl 2): 81-92.
20. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G et al. (2007). Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta 1771: 883-892.
21. Huang X, Li X, Guo B. (2008). KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 283: 29795-29801.
22. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC et al. (1999). The transcriptional program in the response of human fibroblasts to serum. Science 283: 83-87.
23. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
24. Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al. (2008). Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68: 8333-8341.
25. Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S et al. (2008). ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 7: 3739-3750.
26. Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ. (2005). Indole-3-carbinol and 3,30-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 328: 63-69.
27. Lee SH, Yamaguchi K, Kim JS, Eling TE, Safe S, Park Y et al. (2006). Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27: 972-981.
28. Lu D, Wolfgang CD, Hai T. (2006). Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281: 10473-10481.
29. Maekawa T, Sakura H, Kanei-Ishii C, Sudo T, Yoshimura T, Fujisawa J et al. (1989). Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J 8: 2023-2028.
30. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S et al. (2008). ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene 27: 1045-1054.
31. Maekawa T, Shinagawa T, Sano Y, Sakuma T, Nomura S, Nagasaki K et al. (2007). Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol 27: 1730-1744.
32. Miyazaki K, Inoue S, Yamada K, Watanabe M, Liu Q, Watanabe T et al. (2009). Differential usage of alternate promoters of the human stress response gene ATF3 in stress response and cancer cells. Nucleic Acids Res 37: 1438-1451.
33. Oh YK, Lee HJ, Jeong MH, Rhee M, Mo JW, Song EH et al. (2008). Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells. Mol Cancer Res 6: 1232-1249.
34. Ouwens DM, de Ruiter ND, van der Zon GC, Carter AP, Schouten J, van der Burgt C et al. (2002). Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 21: 3782-3793.
35. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
36. Piyanuch R, Sukhthankar M, Wandee G, Baek SJ. (2007). Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett 258: 230-240.
37. Tamura K, Hua B, Adachi S, Guney I, Kawauchi J, Morioka M et al. (2005). Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. Embo J 24: 2590-2601.
38. Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, Williams BR. (2007). Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol 179: 3622-3630.
39. Wolfgang CD, Liang G, Okamoto Y, Allen AE, Hai T. (2000). Transcriptional autorepression of the stress-inducible gene ATF3. J Biol Chem 275: 16865-16870.
40. Woo IS, Kohno T, Inoue K, Ishii S, Yokota J. (2002). Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer. Int J Oncol 20: 527-531.
41. Xue L, Firestone GL, Bjeldanes LF. (2005). DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24: 2343-2353.
42. Yamaguchi K, Lee SH, Kim JS, Wimalasena J, Kitajima S, Baek SJ. (2006). Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res 66: 2376-2384.
43. Yan C, Boyd DD. (2006). ATF3 regulates the stability of p53: a link to cancer. Cell Cycle 5: 926-929.
44. Yan C, Lu D, Hai T, Boyd DD. (2005). Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. Embo J 24: 2425-2435.
45. Yin X, Dewille JW, Hai T. (2008). A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27: 2118-2127.